Drugs / Triplizumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05356351 | May 2022 → Jul 2023 overdue | urinary bladder cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05016973 | Oct 2021 → Sep 2024 | urinary bladder cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triplizumab | “RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W” NCT05356351 ↗ |
| Action | Inhibit | “anti-PD-1 monoclonal antibody” NCT05016973 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-PD-1 monoclonal antibody” NCT05016973 ↗ |
| Route | Intravenous | “Intravenous drip” NCT05016973 ↗ |
| Target | PDCD1 | “recombinant humanized anti-PD-1 monoclonal antibody” NCT05016973 ↗ |